Biotech failure, 2002 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech failure, 2002

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (100)	7/30/2002 11:32:39 PM
From: sim1	of 130

Wilder, is this what you're referring to? 07-24-2002 Aventis Terminating Enrollment in EXPEDITION Study Aventis Press Release Strasbourg, France - Aventis has announced that enrollment in its EXPEDITION study, a global trial evaluating Cariporide in coronary artery bypass graft (CABG) patients, has been terminated on the recommendation of the study's independent Study Steering Committee (SSC) and Data Safety Monitoring Board (DSMB). Cariporide is the first in a class of cardio-protectants that may protect myocardial cells from ischemic damage. The Phase III EXPEDITION study began last year. To date, 5,700 of a target 7,000 participants had enrolled. Aventis will continue the study's six-month follow-up monitoring of currently enrolled patients as specified in the study protocol, and will initiate the detailed safety and efficacy analyses requested by the DSMB to better understand the benefits and risks associated with treatment. The analyses are expected to be completed by early 2003. Decisions regarding regulatory submissions related to Cariporide will be made following the analyses of the follow up data.<snip> aventis.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next